Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac myosin inhibitors (CMIs) are being developed to help patients with hypertrophic obstructive cardiomyopathy (HOCM), a disease in which the heart muscle becomes thickened leading to reduced blood flow out of the heart.
Lilly and insitro team up to develop AI-powered siRNA metabolic drugs – Pharmaceutical Technology
Eli Lilly and insitro’s deal focuses on advancing potential new medicines for metabolic diseases based on targets identified by AI/ML. Credit: ImageFlow via Shutterstock. Eli
October 10, 2024